Heart surgery kits recalled | Sex-specific outcomes after TAVR & SAVR | A new risk calculator | FDA clears tricuspid valve

Specific lots of several procedure kits have been recalled after the FDA identified quality issues during a recent inspection.

TAVR was associated with early benefits for women. After five years, however, outcomes were comparable across the board.

Robert Hawkins, MD, discussed an updated risk calculator—and the latest data on SAVR after TAVR—for a new video interview with Cardiovascular Business.

The Edwards Lifesciences Triformis Resilia is the first dedicated surgical tricuspid valve on the market cleared with data from off-label use of mitral valves.

This recall was put in place due to a risk of the included adhesive not working. Nothing needs to be returned, but clinicians should not use the adhesive that comes inside the procedure kits.

Chair of the department of cardiothoracic surgery at Stanford University School of Medicine, and associate director of the Stanford Cardiovascular Institute, is the new 2026-27 president of the AATS.

Major TAVR policy changes appear to be on the way—should clinicians be excited or concerned? Leading U.S. medical societies are sharing their early reactions.

A left internal mammary artery takedown robot-assisted heart procedure is the latest milestone for an Indian robotics company.